To evaluate the efficacy and safety of cefpiran in the treatment of urogenital tract infections, 30 patients with various kinds of urogenital tract infections were treated with the drug in an opened trial in three hospitals. Cefpiran was intravenously administered 1g daily for 05~7 days. Results showed that for simple urinary tract infections, the cure rate was 78.6% (11/14), the effective rate was 100% (14/14); for complicated urinary tract infections, the cure rate and the effective rate were 70% (7/10) and 80% (8/10) respectively. Overall, the total cure rate, effective rate and the bacterial eradication rate were 73.3% (22/30), 90% (27/30) and 82.1% (23/28) respectively. Adverse events attributed to drug treatment occurred in two patients (6.7%). Additionally, cefpiran was not contraindicated for patients with even moderately impaired renal function. It was concluded that cefpiran is an effective and safe antibiotic for patients with urogenital tract infections.